Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.49 |
| ▸ | PTGDR2 | Q9Y5Y4 | 11/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.36 |
| ▸ | PPOX | P50336 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12316643 | 0.78 | MAP3K14 (0.49) | MAP3K14PTGDR2CSNK2A1PPOXHPGD | |
| SCHEMBL12316538 | 0.73 | MAP3K14 (0.57) | MAP3K14CHEK1KDM4EALDH1A1 | |
| SCHEMBL12316627 | 0.73 | MAP3K14 (0.57) | MAP3K14PTGDR2 | |
| SCHEMBL12316618 | 0.72 | MAP3K14 (0.40) | MAP3K14KMT2A | |
| SCHEMBL12316620 | 0.70 | ALDH1A1 (0.43) | CHEK1CSNK2A1PPOXKDM4EMEN1 | |
| SCHEMBL12316642 | 0.70 | KDM4E (0.42) | CHEK1CSNK2A1PPOXKDM4EMEN1 | |
| SCHEMBL13092731 | 0.69 | MAP3K14 (0.54) | MAP3K14 | |
| SCHEMBL30954162 | 0.68 | TDP1 (0.40) | CSNK2A1PPOXMEN1KMT2APOLB | |
| SCHEMBL27433297 | 0.68 | TDP1 (0.40) | CSNK2A1PPOXMEN1KMT2APOLB | |
| SCHEMBL4521150 | 0.67 | MAP3K14 (0.46) | MAP3K14PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263592-B2 | Equilibrative nucleoside transporter ENT1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2012-09-11 | — | — | US | disclosed |
| US-8263592-B2 | Equilibrative nucleoside transporter ENT1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2012-09-11 | — | — | US | disclosed |
| US-20100280025-A1 | EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-04 | — | — | US | disclosed |
| US-20100280025-A1 | EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280025-A1 | EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS | SLC29A1, SLC29A2, SLC43A3 | MAP3K14 3794/4885PTGDR2 1721/4885CHEK1 4365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.